GoodRx reports that choosing the right asthma inhaler depends on symptom severity and frequency, with options for quick relief and daily control.

A new asthma drug, Lunsekimig, is showing promise in reducing inhaler dependence. Early trials report fewer symptoms, ...

A new asthma drug named Lunsekimig could be the answer for millions who remain dependent on inhalers. Here is what the phase ...

Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight The severe asthma clinical trial analysis ...

Going from a medium-dose inhaled corticosteroid to a biologic for asthma led to significant decreases in exacerbations, ...

Back away from the broom. New research suggests that bringing more grime into your home might actually help your kids’ asthma ...

Sanofi’s (SNY) lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP, the company said on Tuesday. Lunsekimig, a novel bispecific Nanobody VHH, is made ...

A collaborative effort between researchers at the Henan Academy of Innovations in Medical Science, Zhengzhou University, and ...

Sanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a “measured risk.” ...

Patients with respiratory conditions, such as asthma and COPD, are being encouraged to use apps to manage their symptoms.